European Medical Journal15h
Does Dual Antiplatelet Therapy Improve Stroke Outcomes?
A new meta-analysis examines the effects of dual antiplatelet therapy after thrombolysis in minor stroke patients. Findings ...
Medical News Today23h
Anti-amyloid drug may help reduce the risk of early-onset Alzheimer's by 50%
An early Alzheimer's treatment that removes amyloid plaques from the brain many years before symptoms arise may help delay ...
US FDA expands approval for Alnylam's drug to treat rare heart disease
U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...
US FDA approves Alnylam's drug for rare heart condition
U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...
Novartis13h
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
Endocrinology Advisor14h
De-Escalating DAPT to Ticagrelor Monotherapy Cuts Bleeding Risk in Acute Coronary Syndrome
HealthDay News — For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, de-escalating dual antiplatelet therapy (DAPT) to P2Y12 inhibitor monotherapy is ...